ClinicalTrials.gg
RecruitingNCT07417865Updated Feb 18, 2026

ECHO Diabetes FQHC

An observational study in Diabetes, sponsored by University of Florida. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by University of Florida · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
18
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus by University of Florida — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · University of Florida.

Started
2026
with 1 other
Observational
3 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Diabetes Mellitus by University of Florida, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 15th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

3 of the 15 studies in Diabetes Mellitus by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus by University of Florida, or all of them as a file.
02

Study summary

Extension for Community Health Outcomes Diabetes FQHC will provide tele-education to primary care providers (PCP) in Federally Qualified Health Centers in the U.S. using the "hub" and "spoke" training model established in the Project ECHO model. Participating FQHCs (called "spokes") will receive twice monthly tele-education sessions delivered by UF's "hub" team in a 6-month program. The program will be evaluated using pre/posttest provider-level surveys and center-level aggregate data in a stepped-wedge trial design with 3 cohorts of FQHCs. The primary outcomes are the proportion of people >9% HbA1c and technology use (CGM and insulin pump).

Read the detailed description

We will implement a national ECHO Diabetes FQHC program by offering a 6-month tele-education intervention that includes: (1) a virtual orientation and onboarding for FQHCs (2) one-hour tele-ECHO sessions twice monthly with continuing medical education (CME) credits provided (3) real-time support with complex medical decision-making and (4) access to an online repository of diabetes resources for PCPs. The 'hub' team delivering the ECHO Diabetes FQHC program are a nationally recognized multidisciplinary team of adult and pediatric endocrinologists, a clinical health psychologist, Certified Diabetes Care and Education Specialists (CDCES), a registered dietitian, a Certified Exercise Physiologist (CEP), a medical sociologist, PCPs, and health services researchers.

We will evaluate the ECHO Diabetes FQHC program with a stepped-wedge design. This proposal will leverage and expand on key community partnerships established through ECHO Diabetes with two Health Center Controlled Networks (HCCNs), HealthChoiceNetwork (HCN) and AllianceChicago (AC) to accomplish both specific aims. These two Health Center Controlled Networks (HCCNs) have over 100 FQHCs in 29 different states and hold a central data repository for over 7 million unduplicated patients seen for care across these locations. 18 new "spokes" will be recruited from HCN and AC's national network. Covariate-constrained randomization will be used to assign spokes to three cohorts that will have staggered and phased entry into the program in 6-month intervals. Pre- and post-intervention data will be collected at the provider-level and center-level (i.e., "spoke-level") and housed using REDCap® as a central data repository. Provider-level data will include pre and post surveys assessing confidence and knowledge in diabetes care as well as self-reported diabetes care practices. Spoke-level data will include aggregate Health Effectiveness Data and Information Set (HEDIS) metrics for diabetes, Uniform Data System (UDS) metrics for diabetes, mean HbA1c for demographic subgroups, diabetes technology use (CGM and insulin pumps), and referrals for GLP1 and SGL2 medications.

03

Conditions studied

  • Diabetes

Browse trials for

Keywords

  • ECHO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All people 18 and older with diabetes (T1D, T2D) seen for care at participating Federally Qualified Health Centers.

Eligibility criteria

Inclusion Criteria: Federally Qualified Health centers (spokes) are eligible to participate that are part of Health Choice Network (HCN) or Alliance Chicago (AC). All people living with diabetes 18 and older are included in aggregate data sharing to evaluate outcomes.

-

Exclusion Criteria:

  • Non FQHC, not part of HCN or AC
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
18 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    6-8 Federally Qualified Health Centers that participate in the ECHO Diabetes tele-education program for PCPs

    Behavioral: ECHO Diabetes tele-education

  • Cohort 2

    6-8 Federally Qualified Health Centers that participate in the ECHO Diabetes tele-education program for PCPs

    Behavioral: ECHO Diabetes tele-education

  • Cohort 3

    6-8 FQHCs that participate in the ECHO Diabetes tele-education program for PCPs

    Behavioral: ECHO Diabetes tele-education

Interventions

  • BehavioralECHO Diabetes tele-education

    All cohorts will be given the ECHO Diabetes tele-education program -- one hour sessions twice monthly for 6 months for PCP in FQHCs

06

What researchers measure

Primary outcomes

  1. HEDIS >9% HbA1c

    Proportion of FQHC population with \>9% HbA1c

    Time frame: From baseline to 12-months following

  2. Technology Use

    CGM and Pump Use

    Time frame: From baseline to 12-months following

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Aggregate data will be shared upon reasonable requests made to project PIs

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Upon publication of data or per request of journals via the publication process

Access criteria: Any one making a reasonable request for data -- all data is aggregated and do not include PHI or identifiers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jul 2028, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 18, 2026
StartActual
Jan 22, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07417865
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Jan 22, 2026
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Feb 18, 2026

Study contacts

Ashby F Walker, Ph.D.
Contact
afwalker@ufl.edu
352-273-8278
Ashby F Walker, Ph.D.
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion